Home — The Jenner Institute

Have we beaten Malaria?

More than half a million people die of malaria every year. With two vaccines recommended for use against malaria, Lisa Stockdale (Jenner Institute) and Andrew Duncan (Biochemistry) from the University of Oxford will discuss what the prospects are for eliminating malaria and how long it might take. Explore the future of healthcare with engaging talks, hands-on workshops, and exciting activities showcasing groundbreaking innovations. Wednesday 11 September / 18:30-22:00 / Science Museum, London.

Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine

Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.

The Jenner Institute Early Researchers Symposium 2024

On June 7, 2024, the second annual Jenner Institute Early Researchers Symposium (JERS) was held at St Anne's College, bringing together a vibrant community of over 80 DPhil Students, Research Assistants, Technicians and Apprentices from across the Nuffield Department of Medicine to network, share their research and discuss career aspirations.

Public event: Tuberculosis - vaccines, diagnostics and experience

On Wednesday 5th June, the University of Oxford is marking the 100th anniversary of the death of Franz Kafka, who died in 1924 of tuberculosis, with a programme of activities celebrating his works and enduring legacy. The event will include a talk by Prof Helen McShane, Head of the Jenner Institute TB Vaccine Programme.

Jenner Institute director receives award for an Outstanding Contribution to Translational Medicine

The Director of the Jenner Institute, Professor Sir Adrian Hill, was announced as the 2024 recipient of the UK Association of Physicians’ award for an Outstanding Contribution to Translational Medicine. He was presented with the award at a ceremony during the annual meeting held in Newcastle 23-24 May, 2024.

Vice-Chancellor's Award for R21 Malaria vaccine team

The R21/Matrix-M Malaria vaccine clinical development programme team from the Jenner Institute has won the Innovation and Commercialisation category of the University of Oxford Vice-Chancellor’s Awards 2024. The team, led by Prof. Sir Adrian Hill, is behind the clinical development of the R21 Malaria vaccine which is due to be rolled out in the first African countries in the next months. The Vice-Chancellor’s Awards recognise the achievements and celebrate success across the University.

FCDO Minister meets with Jenner Institute researchers

Mr. Mitchell, along with Professor Charlotte Watts, FCDO Chief Scientific Adviser and Director for Research and Evidence, toured the research facilities of the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute, following the government announcement in Davos of an additional £10 million to support the effective roll-out of two new malaria vaccines both developed by British science.

Scientists receive the European Hector Research Award for HIV

The AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out

The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.

Oxford malaria vaccine receives regulatory clearance for use in Burkina Faso

The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).

African Phase I HIV vaccine trial shows encouraging preliminary results

The clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.

Prof Adrian Hill, Lakshmi Mittal & Family Professor Of Vaccinology and Director of the Jenner Institute; and Dr César López-Camacho, Senior Researcher and Group Leader for mRNA technologies, with Ms Josefa González-Blanco at the Jenner Institute.

Mexican Ambassador visits Jenner Institute

The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.

Romain Guyon awarded 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

History of the COVID-19 vaccine

The Oxford / AstraZeneca COVID-19 vaccine is estimated to have saved more than six million lives – more than any other COVID vaccine, during the first year of use.

Find out more

Support us

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

Make a gift

Publications

COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review
Journal article

Galgut O. et al, (2024), Vaccine: X, 20
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.
Journal article

Asor R. et al, (2024), Proceedings of the National Academy of Sciences of the United States of America, 121
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Journal article

Harrison TE. et al, (2024), EMBO Mol Med

More publications

Latest News

Get regular updates on social media.

Seminars

mRNA vaccine optimization for infectious diseases

Wednesday, 16 October 2024, 11am to 12pm

More seminars